Today's Date: October 24, 2021
Empowering Leadership in Latina Athletes (ELLA) Prepares Young Female Athletes for Success   •   Big Brothers Big Sisters of Greater Los Angeles Honors Michael E. Kassan, Stacy Green and The Los Angeles Rams Raising Over $1,0   •   Walgreens Now Offering Moderna and Johnson & Johnson COVID-19 Vaccine Booster Shots Nationwide   •   MSD joins hands with Emirates Oncology Society and Friends of Cancer Patients for EMBRACE campaign to support Breast Cancer Awar   •   Cook County Treasurer Maria Pappas partners with Candace Jordan and Black Men United in a North Michigan Avenue random act of ki   •   Groupon Announces Date of Third Quarter 2021 Earnings Release and Conference Call   •   Korean War Naval Aviator Reunites With His Combat Fighter Plane   •   Redbox to Ring the NASDAQ Stock Market Opening Bell   •   Aleada Consulting Accepted Into Forbes Technology Council   •   Navy vs UC Face-Off to Start with Patriotic Team Fastrax Skydive   •   Utz Brands to Report Third Quarter 2021 Financial Results on November 11, 2021   •   Netcapital Advisors’ Upcoming Women in Private Equity Webinar Series to Feature Keynote Speaker Gloria Feldt on the Topic   •   Transformative Justice Coalition (TJC) Press Conference and March: "Justice And the First Amendment "   •   Smokeball Ushers in Its Fourth-Annual Season of Giving   •   Ángela Aguilar And Manzanita Sol Join Forces To Give Back To Los Angeles Community For Día De Los Muertos   •   Macy’s, Inc. Board of Directors Declares Quarterly Dividend   •   Foxy P's 2021 African Princes Of Comedy Tour Ramps For Tomorrow Night In The City Of Brotherly Love   •   Aramark Celebrates LGBTQ+ Pride by Naming Mark Wallace the 2021 Ian Bailey Pride of Aramark Award Recipient   •   18th Annual LeadingAge Ziegler 200 Report Ranks Not-For-Profit Senior Living Providers, Shares Outlook On Industry Trends   •   Closing Achievement Gaps for African American Young Men in San Francisco
Bookmark and Share

Gynesonics Announces FDA Clearance of Next Generation Sonata System

REDWOOD CITY, Calif. , September 16 /Businesswire/ - Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today the Food and Drug Administration (FDA) has given clearance of the Sonata® System 2.2 which provides important new benefits for facilities, physicians and patients. These benefits include: a 20% reduction in the smallest ablation size setting, which greatly increases the ability to treat fibroids in tighter anatomical locations; new software advances that allow the surgeon to control all aspects of the ablation from the handpiece without requiring OR staff to separately adjust settings; and changes that enable the surgeon to adjust all ultrasound settings directly from the sterile field. The system includes a new reusable cable. Additionally, the novel intrauterine ultrasound reusable probe is now validated to be sterilized using the family of STERIS V-PRO® low temperature sterilization systems, commonly available at hospitals.

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics. “These changes provide real benefit to the treating physicians and to a greater number of women seeking relief from their symptoms caused by fibroids. Additionally, the ability to make use of the widely available STERIS V-PRO family of low temperature sterilization systems, and the notable engineering achievement of the new, reusable RF handpiece cable have cost benefits for the facilities and reduce the procedural waste. This is a positive advance for women, physicians and medical center facilities.”

The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids. The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wider range of fibroid types, sizes, and locations than hysteroscopic myomectomy. Fibroids are treated from within the uterus, so treatment with the Sonata System requires no incisions, no tissue is surgically removed, and the uterus is retained.

“Gynesonics has a long and successful history of meaningful innovation, and changes that have real benefits to the healthcare system and to the patient. The new Sonata System 2.2 is a continuation of this commitment to innovation. The positive timing of this clearance coincides with the accelerated demand for Sonata,” said Chris Owens, President and CEO of Gynesonics. “The new system provides greater features, ease-of-use and flexibility to physicians who wish to offer Sonata TFA to their patients and the millions of women who have been waiting for an option that does not require invasive, incisional surgery.”

For more information on the Sonata System, go to www.gynesonics.com.

About Sonata System

The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer. The System includes a proprietary graphical user interface (SMART Guide), enabling the operator to target fibroids and optimize treatment. The Sonata System provides incision-free transcervical access for a uterus-preserving fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. Most side effects are typically minor and temporary. The Sonata System is CE marked and is approved for sale in the European Union, the United Kingdom, and the United States.

About Fibroids

Fibroids are benign growths in or around the uterus. They are common and most women develop them during childbearing age. In the U.S., around 70% of white women and more than 80% of black women will have uterine fibroids before the age of 50. Problematic fibroids can range in size from a raisin to a grapefruit, and symptoms may worsen over time if fibroids are left untreated. 20% to 50% of women with fibroids are symptomatic and each year in the U.S., more than 2 million women undergo treatment for uterine fibroids. Women with symptomatic fibroids may present one or more of the following:

  • Abnormal uterine bleeding/menorrhagia
  • Abdominopelvic pain/pressure
  • Increased abdominal girth
  • Urinary frequency
  • Constipation
  • Subfertility
  • Pregnancy complications
  • Dyspareunia (painful intercourse)

About Gynesonics

Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. Gynesonics headquarters is in Redwood City, CA. For more information, go to www.gynesonics.com.


STORY TAGS: United States, North America, California, Product/Service, Medical Devices, FDA, Health, Consumer, Surgery, Women,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News